Authors' affiliations

J M Marchant, I B Masters, S M Taylor, A B Chang, Department of Respiratory Medicine, Royal Children's Hospital, Brisbane, Australia J M Marchant, I B Masters, A B Chang, School of Medicine, Discipline of Paediatrics and Child Health, University of Queensland, Royal Children's Hospital, Brisbane, Australia

JMM is supported by the Royal Children's Hospital Foundation, Brisbane and the TSANZ/Allen and Hanbury's Paediatric Respiratory Medicine Career Development Fellowship. ABC is funded by a Practitioner Fellowship from the National Health and Medical Research Council,

Conflict of interest: none known.

REFERENCES

- Britt H, Miller GC, Knox S, et al. Bettering the evaluation and care of health: a study of general practice activity, Australian Institute of Health and Welfare, 2002.
- 2 Bush A. Paediatric problems of cough. Pulm Pharmacol Ther 2002;15:309-15
- 3 Mello CJ, Irwin RS, Curley FJ. Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med 1996:156:997-1003
- 4 De Jongste JC, Shields MD. Cough. 2: Chronic cough in children, Thorax 2003;58:998–1003.
- Chang AB, Robertson CF. Cough in children. Med J Aust 2000;172:122-5.
- Chang AB, Asher MI. A review of cough in children. J Asthma 2001;38:299-309.
- Chang AB. Cough: are children really different to adults? Cough 2005;1:7.
- Chang AB. Causes of cough, assessment and measurement in children. In: Widdicombe JG, Chung F, Boushey H, eds. Cough: mechanisms, causes and therapy. Oxford: Blackwell Science, 2003.

- 9 Chang AB, Powell CV. Non-specific cough in children: diagnosis and treatment. Hosp Med 1998;**59**:680-4.
- Chang AB. State of the art: cough, cough receptors, and asthma in children. Pediatr Pulmonol 1999;28:59–70.
- Chang AB, Phelan PD, Sawyer SM, et al. Airway hyperresponsiveness and cough-receptor sensitivity in children with recurrent cough. Am J Respir Crit Care Med 1997;**155**:1935–9.
- 12 Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990;141:640-7.
- 13 Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998;114:81-1335.
- 14 Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006;129:1132-41.
- 15 Chang AB, Newman RG, Carlin J, et al. Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method. Eur Respir J 1998;11:462-6.
- 16 Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002;57:178-82.
- Copley SJ, Bush A. Series: Imaging. HRCT of paediatric lung disease. Paediatr Respir Rev 2000;1:141-7.
- 18 Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32(Suppl
- Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough. Executive summary: ACCP evidence-based clinical practice guidelines,
- 20 Chang AB, Gaffney JT, Eastburn MM, et al. Cough quality in children: a
- comparison of subjective vs. bronchoscopic findings. Respir Res 2005;6:3. Marchant J, Morris P, Gaffney J, et al. Antibiotics for prolonged moist cough
- in children. Cochrane Database Syst Rev 2005;(4):CD004822.
 Thomson F, Masters IB, Chang AB. Persistent cough in children: overuse of medications. J Paediatr Child Health 2002;38:578–81.

LUNG ALERT

Inhaled corticosteroid use in young children at high risk of asthma

▲ Guilbert WT, Morgan WJ, Zeiger RS, *et al.* Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006;**354**:1985–7

•he PEAK (Prevention of Early Asthma in Kids) clinical trial tested the hypothesis that the natural history of wheezing in early life may be altered by the continuous administration of inhaled corticosteroids. This multicentre, double blind, placebo controlled trial randomised 285 preschool children (aged 2-3 years) with a positive asthma predictive index to inhaled fluticasone or masked placebo for 2 years, followed by a 1 year observation period without study medication. The primary outcome was the difference between study groups in the proportion of episode-free days during the observation period.

During the observation year no significant differences were seen between the two groups in the proportion of episode-free days, exacerbation frequency, or lung function. Whilst on treatment, children receiving fluticasone had a greater proportion of episode-free days (93.2% v 88.4%, p = 0.006) and a lower rate of exacerbations $(57.4 \text{ } v \text{ } 89.4 \text{ } \text{ } \text{events } \text{per } 100 \text{ } \text{ } 100 \text{ } 1000 \text{ } 100 \text{ } 100 \text{ } 1000 \text{ } 100 \text{ } 1000 \text{ } 1000 \text{$ child/years, p<0.001) and the supplementary use of various additional medications (all p < 0.001).

Decreased growth velocity was observed in the inhaled corticosteroid group during the first year. The growth rate was similar during the second year and, although growth accelerated in the corticosteroid group during the observation year, the height difference at the trial end was 0.7 cm (p = 0.008).

The authors conclude that the natural course of asthma in young children at high risk for subsequent asthma is not modified by 2 years of treatment with inhaled corticosteroid. However, the treatment did reduce the burden of illness. This study shows that inhaled corticosteroid can be used to control active disease but not to prevent asthma in high risk preschool children.

Clinical Research Fellow, Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK; lindseymclure@yahoo.co.uk